Skip to main content

Advertisement

SpringerLink
Log in

Lewy bodies and dementia

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

The discovery of widely distributed Lewy bodies (LBs) in the brains of patients with dementia has stimulated much clinical and pathologic inquiry. This clinico-pathologic syndrome is now referred to as dementia with Lewy bodies (DLB). Diagnostic criteria for DLB proposed at a workshop in 1995 are receiving detailed scrutiny. The criteria are complex to apply, and appear to have high specificity, but variable sensitivity. Neuropathologic studies have been aided by the development of probes against a-synuclein, a key component of LBs. Widespread LBs in limbic or cortical areas contribute to dementia. Pharmacologic management of cognitive and behavioral symptoms in patients with DLB is being explored. There is evidence that cholinesterase inhibitors may have beneficial effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kosaka K: Diffuse Lewy body disease in Japan. J Neurol 1990, 237:197–204.

    Article  PubMed  CAS  Google Scholar 

  2. McKeith IG, Galasko D, Kosaka K, et al.: Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology 1996, 47:1113–1124.

    PubMed  CAS  Google Scholar 

  3. Polymeropolous MH, Lavedan C, Leroy E, et al.: Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276:2045–2047.

    Article  Google Scholar 

  4. Kruger R, Kuhn W, Muller T, et al.: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 1998, 18:106–108.

    Article  PubMed  CAS  Google Scholar 

  5. Spillantini MG, Schmidt ML, Lee VM, et al.: Alpha-synuclein in Lewy bodies. Nature 1997, 388:839–840.

    Article  PubMed  CAS  Google Scholar 

  6. Takeda A, Mallory M, Sundsmo M, et al.: Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol 1998, 152:367–372.

    PubMed  CAS  Google Scholar 

  7. Wakabayashi K, Matsumoto K, Takayama K, et al.: NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson’s disease. Neurosci Lett 1997, 239:45–48.

    Article  PubMed  CAS  Google Scholar 

  8. Duda JE, Giasson BI, Gur TL, et al.: Immunohistochemical and biochemical studies demonstrate a distinct profile of alphasynuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 2000, 59:830–841.

    PubMed  CAS  Google Scholar 

  9. Clayton DF, George JM: Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999, 58:120–129.

    Article  PubMed  CAS  Google Scholar 

  10. El-Agnaf OM, Irvine GB: Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J Struct Biol 2000, 130:300–309.

    Article  PubMed  CAS  Google Scholar 

  11. Gomez-Tortosa E, Newell K, Irizarry MC, et al.: Alpha-synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathologica 2000, 99:352–357.

    Article  PubMed  CAS  Google Scholar 

  12. Spillantini MG, Crowther RA, Jakes R, et al.: Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Nat Acad Sci 1998, 95:6469–6473.

    Article  PubMed  CAS  Google Scholar 

  13. Baba M, Nakajo S, Tu PH, et al.: Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol 1998, 152:879–884.

    PubMed  CAS  Google Scholar 

  14. Conway KA, Lee SJ, Rochet JC, et al.: Acceleration of oligomerization, not fibrillization, ia a shared property of both alphasynuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 2000, 97:571–576.

    Article  PubMed  CAS  Google Scholar 

  15. Hashimoto M, Hsu LJ, Xia Y, et al.: Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 1999, 10:717–721.

    Article  PubMed  CAS  Google Scholar 

  16. Souza JM, Giasson BI, Chen Q, et al.: Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 2000, 275:18344–18349.

    Article  PubMed  CAS  Google Scholar 

  17. Masliah E, Rockenstein E, Veinbergs I, et al.: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265–1269. A transgenic mouse line that overexpressed wild-type human a-synuclein showed progressive motor deficits, loss of dopaminergic terminals in the basal ganglia, and a-synuclein-containing inclusions in neurons of the cortex, hippocampus, and substantia nigra. A key implication is that accumulation of insoluble intracellular a-synuclein may be a causal factor in Lewy body disorders.

    Article  PubMed  CAS  Google Scholar 

  18. Van der Putten H, Wiederhold KH, Probst A, et al.: Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000, 20:6021–6029.

    PubMed  Google Scholar 

  19. Feany MB, Bender WW: A Drosophila model of Parkinson’s disease. Nature 2000, 404:394–398. Normal and mutant a-synuclein expressed in Drosophila resulted in adult-onset motor deficits in these flies, with a-synuclein inclusions morphologically resembling Lewy bodies (LB) in dopaminergic neurons. This simple and convenient model adds to the body of evidence that a-synuclein accumulation is central to LB disorders, and may be used to test potential treatments.

    Article  PubMed  CAS  Google Scholar 

  20. Giasson BI, Duda JE, Murray IV, et al.: Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985–989. Novel monoclonal antibodies were raised against nitrated forms of a-synuclein. Nitrated a-synuclein was readily identified in Lewy bodies (LBs) and Lewy neurites. Oxidation may, therefore, be an important and potentially treatable mechanism that promotes the aggregation of a-synuclein in LB disorders.

    Article  PubMed  CAS  Google Scholar 

  21. Lim A, Tsuang D, Kukull W, et al.: Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc 1999, 47:564–569.

    PubMed  CAS  Google Scholar 

  22. Mattila PM, Roytta M, Torikka H, et al.: Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson’s disease. Acta Neuropathologica 1998, 95:576–582.

    Article  PubMed  CAS  Google Scholar 

  23. Hurtig HI, Trojanowski JQ, Galvin J, et al.: Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000, 54:1916–1921. The severity of a-synuclein-stained Lewy bodies (LBs) and neurites was rated in the hippocampus and cortical regions in patients with Parkinson’s disease (PD). The burden of cortical LB was the strongest discriminant between demented and nondemented PD patients, ahead of Alzheimer’s disease pathology. This paper adds strongly to the body of evidence that widespread LBs are markers of dementia in PD.

    PubMed  CAS  Google Scholar 

  24. Hamilton RL: Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000, 10:378–384. a-synuclein immunostaining identified Lewy bodies (LBs) in about 60% of patients with dementia who met histopathologic criteria for Alzheimer’s disease. The most frequent locus of LB was the amygdala. Their clinical significance of LBs at this site remains to be determined.

    Article  PubMed  CAS  Google Scholar 

  25. Lippa CF, Fujiwara H, Mann DM, et al.: Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein. Am J Pathol 1998, 153:1365–1370. About 60% of early-onset familial Alzheimer’s disease (AD) cases associated with mutations in presenilins or amyloid precursor protein showed Lewy body (LB) pathology in addition to AD. This reinforces the concept that factors that lead to AD lesions may also promote LB formation.

    PubMed  CAS  Google Scholar 

  26. Yamazaki M, Arai Y, Baba M, et al.: Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonismdementia complex of Guam. J Neuropathol Exp Neurol 2000, 59:585–591.

    PubMed  CAS  Google Scholar 

  27. Arawaka S, Saito Y, Murayama S, Mori H: Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 1998, 51:887–889.

    PubMed  CAS  Google Scholar 

  28. Haroutunian V, Serby M, Purohit DP, et al.: Contribution of Lewy Body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol 2000, 57:1145–1150. Lewy body (LB) and Alzheimer’s disease (AD) lesions were quantitatively studied in a large cohort of elderly patients on whom information about the severity of dementia close to the time of death was obtained. The LB burden correlated with dementia severity independent of AD lesions. Again, this supports the concept that the burden of LB in cortical and hippocampal regions contributes to dementia.

    Article  PubMed  CAS  Google Scholar 

  29. Mattila PM, Rinne JO, Helenius H, et al.: Alpha-synucleinimmunoreactive Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathologica 2000, 100:285–290.

    Article  PubMed  CAS  Google Scholar 

  30. Forno LS: Concentric hyaline neuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 1969, 17:557–575.

    PubMed  CAS  Google Scholar 

  31. Gibb W, Lees A: The relevance of the Lewy Body to the pathogenesis of idopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988, 51:745–752.

    Article  PubMed  CAS  Google Scholar 

  32. Perry R, Irving D, Tomlinson B: Lewy body prevalence in aging brain: relationship to neuropsychiatric disorders, Alzheimertype pathology and catecholaminergic nuclei. J Neurol Sci 1990, 100:223–233.

    Article  PubMed  CAS  Google Scholar 

  33. Mega MS, Masterman DL, Benson DF, et al.: Dementia with Lewy bodies: reliability and validity of clinical and pathological criteria. Neurology 1996, 47:403–409.

    Google Scholar 

  34. Hohl U, Tieraboschi P, Hansen LA, et al.: Diagnostic accuracy of dementia with Lewy bodies. Neurology 2000, 57:347–351.

    Article  CAS  Google Scholar 

  35. Verghese J, Crystal HA, Dickson DW, Lipton RB: Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999, 53:1974–1982.

    PubMed  CAS  Google Scholar 

  36. Lopez OL, Hamilton RL, Becker JT, et al.: Severity of cognitive impairment and the clinical diagnosis of AD with Lewy Bodies. Neurology 2000, 54:1780–1787. Clinical features were compared in patients with dementia who had pathology of Alzheimer’s disease (AD) or AD plus dementia with Lewy bodies (DLB). The two groups overlapped considerably, and only in moderate and severe dementia was there an excess of rigidity, indicating Parkinsonism, in AD plus DLB. This study identifies low accuracy of the DLB clinical criteria, especially when early diagnosis is attempted, when both AD and DLB pathology co-occur.

    PubMed  CAS  Google Scholar 

  37. Gomez-Isla T, Growdon WB, McNamara M, et al.: Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999, 53:2003–2009.

    PubMed  CAS  Google Scholar 

  38. McKeith IG, Ballard CG, Perry RH, et al.: Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000, 54:1050–1058. A prospective study of dementia with Lewy bodies (DLB) and Alzheimer’s disease clinical diagnostic criteria, which found high sensitivity and specificity for the diagnosis of DLB. Identification of fluctuation, which other research groups have found difficult, was an important component of this study.

    PubMed  CAS  Google Scholar 

  39. Walker MP, Ayre GA, Cummings JL, et al.: Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology 2000, 54:1616–1624.

    PubMed  CAS  Google Scholar 

  40. Boeve BF, Silber MH, Ferman TK, et al.: REM sleep disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology 1998, 52:363–370.

    Google Scholar 

  41. Galasko D, Katzman R, Salmon DP: Clinical and neuropathological findings in Lewy body dementia. Brain Cognition 1996, 31:176–185.

    Article  Google Scholar 

  42. Salmon DP, Galasko D, Hansen LA, et al.: Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cognition 1996, 31:148–165.

    Article  CAS  Google Scholar 

  43. Shimomura T, Mori E, Yamashita H, et al.: Cognitive loss in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 1998, 55:1547–1552.

    Article  PubMed  CAS  Google Scholar 

  44. Mori E, Shimomura T, Fujimori M, et al.: Visuospatial impairment in dementia with Lewy bodies. Arch Neurol 2000, 57:489–493.

    Article  PubMed  CAS  Google Scholar 

  45. Ishii K, Imamura T, Sasaki M. et al.: Regulation of cerebal glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology 1999, 52:951–957.

    Google Scholar 

  46. Hashimoto M, Kitagaki H, Imamura T, et al.: Medial temporal lobe atrophy in dementia with Lewy bodies: a volumetric MRI study. Neurology 1998, 51:357–362.

    PubMed  CAS  Google Scholar 

  47. Barber R, Ballard C, McKeith IG, et al.: MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000, 54:1304–1309.

    PubMed  CAS  Google Scholar 

  48. McKeith I, Del Ser T, Spano PF, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000, 356:2031–2036. The first randomized clinical trial to demonstrate that cholinesterase inhibitor treatment benefits patients with dementia with Lewy bodies. Active treatment was well tolerated and led to improvement of behavioral symptoms, especially inertia and apathy, and of performance of a computerized cognitive battery. The impact of these changes on daily function or overall cognition is less clear and warrants further study.

    Article  PubMed  CAS  Google Scholar 

  49. Ballard C, Grace J, McKeith I, Holmes C: Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease. Lancet 1998, 351:1032–1033.

    Article  PubMed  CAS  Google Scholar 

  50. Goetz C, Blasucci LM, Leurgans S, Pappert, EJ: Olanzapine and clozapine. Comparative effects on motor function in hallucinating PD patients. Neurology 2000, 55:789–794.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Veterans Affairs Medical Center, 127, 3350 La Jolla Village Drive, 92161, San Diego, CA, USA

    Douglas Galasko MD

Authors
  1. Douglas Galasko MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galasko, D. Lewy bodies and dementia. Curr Neurol Neurosci Rep 1, 435–441 (2001). https://doi.org/10.1007/s11910-001-0103-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-001-0103-x

Keywords

Search

Navigation